When Pfizer discontinued Exubera, its disastrously unsuccessful inhaled insulin, in 2007, the soul searching wasn't limited to Manhattan's East 42nd Street.
BLAIR JACKSON
Vice President of Business Development and New Product Planning, Alkermes
(JOHN HALPERN)
When Pfizer discontinued Exubera, its disastrously unsuccessful inhaled insulin, in 2007, the soul searching wasn't limited to Manhattan's East 42nd Street. One of the companies that found itself reeling was Alkermes, a biotech with deep experience in drug delivery, which had been partnering with Lilly on a prospective inhaled insulin product—one that Lilly cancelled not long after Exubera bit the dust."That caused us to really take stock of what we were doing and how we were moving forward," recalls Blair Jackson. At the time the Lilly project was pulled, Alkermes had only one proprietary program in development, Vivitrol (naltrexone) for alchohol dependency; the rest of the company's resources were focused on developing drugs for partners. Suddenly that ratio looked wrong. "Over the course of the next year," says Jackson, "we moved from being a single- to a multiple-product developing company. We ended up doing more than 25 clinical and nonclincal studies. We had five or six regulatory filings. It was a fundamental shift in the organization." And leading the way was Jackson's program leadership team. The lessons of turning the battleship? "One of the most important things is flexibility," says Jackson. "When you look at severeal development programs at once, you find that the plan going in at the beginning of the year is completely different from the plan coming out at the back end. But what does remain the same is the budget."
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.